Careers
|
Partnerships
|
Contact
|
Login
Response Biomedical logo

Company

Response Biomedical Corp. (Response) has been at the forefront of acute care testing for over 35 years, dedicated to supporting life-saving care through rapid and reliable diagnostics. Headquartered in Canada, we supply high-quality immunoassays to improve patient outcomes because every test result can change a life.
Got Your Back
We build trust through
honesty, accountability,
and mutual support
Take the Lead
We lead by example,
with vision, accountability,
and initiative
Better Every Day
We embrace growth
through continuous learning, feedback, and improvement
Find A Way
We are resourceful,
solution-oriented, and
resilient in the face of challenges

What We Do

The RAMP platform provides acute care diagnostic testing designed to support rapid clinical decision-making. We understand the stresses associated with achieving a fast and accurate diagnosis when every minute counts. We are committed to providing lab-quality results within minutes that medical teams can trust, while reducing the total cost of care.

Who We Are

Response is focused on enabling our strong network of partners to be leaders in their markets by providing high quality diagnostic tests and exceptional levels of support. Response fosters a values-based culture, and we believe the people we work with internally and externally are the cornerstone of our success. Response has a world-class R&D and manufacturing facility in beautiful Vancouver, Canada and our Quality Management System (QMS) is ISO 13485:2016 and MDSAP certified by Intertek. 

Our Purpose

Our core purpose is to guide patient care when answers most. We work tirelessly to ensure that patients receive diagnostic results with speed, precision and accuracy so their medical teams can quickly and confidently make informed patient management decisions.

Our Promise to You

We commit to responding to any request within 24 hours, or else we will pay you $500. This commitment reflects our unwavering passion and dedication to providing the best customer experience around the clock. Reach out to us through our 24/7 Response support line at 1-866-525-7267. Our dedicated team is always available to answer any questions or concerns.

Leaders in Our Industry

Response focuses on providing diagnostic tools that aid in the diagnosis of
life-threatening diseases, and we are passionate about raising the bar in acute care diagnostics.

Taso Tsonis, CPA, CA

Interim CEO,
and CFO

Angela Carter

Vice President,
Global Channel Strategy

Ellen Green

senior director,
Quality, regulatory, clinical

Contact Our Specialists

24 hour Technical Support available to all RAMP Customers

Faster

Improves turnaround time
for faster triage

Accurate

Provides high quality results
with built in QC

Reliable

Enables clinicians to make
informed decisions
©2025 Response Biomedical. All Rights reserved

You will be able to participate in this research study if you are:

  • 18 years of age or older.
  • In good health.
  • Willing to voluntarily agree to sign the consent form.

You will not be able to participate in this research study if:

  • You are considered/consider yourself to be a vulnerable subject (e.g., nursing home residents, institutionalized persons, pregnant and nursing women, children under the age of 19, prisoners, or persons with decisional incapacity).
  • You are currently diagnosed with, or have a history of, underlying major medical conditions (for example: heart disease, hypertension, stroke, renal disease, diabetes and bleeding disorders).
  • You are actively in hemodialysis treatment.
  • You have been told that you have HIV, chronic active hepatitis B, or chronic, active hepatitis C.
  • You have been hospitalized (for more than 24 hours) in the past three months.
  • You are actively receiving treatment or monitoring for certain cancers (excluding non-melanoma skin cancers and localized prostate cancer not requiring systemic therapy).
  • You are already enrolled in this study.
  • You are unable and/or unwilling to provide informed consent.
If you are interested in participating in this study, you can schedule a time to virtually meet with the clinical team at Response Biomedical. During your online meeting, Response Biomedical will send you a self-assessment questionnaire via DocuSign to determine eligibility. If you are eligbile to participate, a team member will explain the study in detail, review the consent form with you, and send the consent form to you for electronic signature. Once you have signed the consent form, the study staff will arrange an appointment for you at a nearby LifeLabs location.

To participate in this study at a LifeLabs location, you will need to be able to print a paper copy of the requisition to take with you to your appointment. If you do not have access to a printer but would still like to participate, you can book an appointment at the Response Biomedical location or attend a community collection event.
At your LifeLabs appointment, a trained LifeLabs professional will collect two (2) 4 mL tubes of whole blood—approximately two teaspoons.
After collection, your blood sample will be sent to Response Biomedical, where a trained operator will use it to perform the RAMP® hs-TnI test.

Ellen Green, BS/BMgmt, RAC

Senior Director, Quality, Regulatory, and Clinical
ellen
Ellen Green returned to Response in 2025, bringing 25 years of biotech, pharmaceutical, and IVD experience in regulatory, clinical, quality, operations, and project management. In her role, Ellen oversees critical functions, including global regulatory registrations and compliance, quality system management, and clinical strategy. With a passion for global access to trusted medical care, Ellen drives clinical projects forward with a focus to minimize time to market while ensuring quality products can be relied upon for actionable results in global jurisdictions. A strategic thinker and creative problem solver, Ellen leads the development and execution of our long-term quality, regulatory, and clinical strategy. Prior to joining our team, Ellen’s background in project management led her to QLT Inc where she developed a keen interest in the biotech industry. She later honed her skills in strategic planning, operations, clinical trial management, and global regulations at companies such as iCo Therapeutics Inc., PYRAMID Laboratories Inc, and Qu Biologics Inc.

Book A Demo

"*" indicates required fields

Name*

Meet Us at the Event

"*" indicates required fields

Name*

Technical Support

"*" indicates required fields

Name*

Get A Quote

"*" indicates required fields

Name*

Partnership

"*" indicates required fields

Name*

Angela Carter BSC (Hons)

Vice President, Global Channel Strategy
Response Biomedical team member Angela
“We’re working strategically with our partners to help them be leaders in their markets.” Angela Carter has been with Response for 20 years and is responsible for our commercial efforts and support services. Angela plays a key role in working strategically with Response's channel partners to grow our customer base and she is the voice of the customer at Response. Angela is passionate about international business and her in-depth clinical and technical knowledge is a key driver for growth at Response. She has extensive experience in in vitro diagnostics and near patient testing with expertise in sales and marketing, laboratory operations, analytical development, QC and compliance. Prior to Response, Angela's background in biochemistry led to work in molecular biology and proteomics at various labs at SFU, UBC and the University of Toronto. Angela's shift to industry began at ID Biomedical where she worked in assay development for drug-resistant bacteria and her passion for diagnostics grew through her development of an innovative diagnostics design for a novel cancer marker at Kinetek Biotechnology.

TASO Tsonis, CPA, CA

Interim CEO and CFO
Response Biomedical team member Taso
Taso Tsonis, joined Response in 2011, bringing a wealth of experience in global finance, accounting, and assurance and stepped into the role of interim CEO in January 2025. As a key member of our leadership team, Taso plays a pivotal role in steering the financial aspects of our operations. In his capacity, Taso oversees critical functions, including budgeting, forecasting, financial controls, and compliance. With a keen eye on maintaining effective financial management, he ensures that our company meets its reporting requirements and manages treasury functions adeptly. A strategic thinker, Taso leads the development and execution of our global long-term financial strategy. His commitment to driving profitable growth has been instrumental in the company’s success. Prior to joining our team, Taso honed his skills in public accounting with Ernst & Young, adding a valuable layer of expertise to our financial leadership. His dedication and proficiency contribute significantly to our overall financial health and success.

You will be able to participate in this research study if you are:

  • 18 years of age or older.
  • In good health.
  • Willing to voluntarily agree to sign the consent form.

You will not be able to participate in this research study if:

  • You are considered/consider yourself to be a vulnerable subject (e.g., nursing home residents, institutionalized persons, pregnant and nursing women, children under the age of 19, prisoners, or persons with decisional incapacity).
  • You are currently diagnosed with, or have a history of, underlying major medical conditions (for example: heart disease, hypertension, stroke, renal disease, diabetes and bleeding disorders).
  • You are actively in hemodialysis treatment.
  • You have been told that you have HIV, chronic active hepatitis B, or chronic, active hepatitis C.
  • You have been hospitalized (for more than 24 hours) in the past three months.
  • You are actively receiving treatment or monitoring for certain cancers (excluding non-melanoma skin cancers and localized prostate cancer not requiring systemic therapy).
  • You are already enrolled in this study.
  • You are unable and/or unwilling to provide informed consent.
If you agree to take part in this study, study staff will discuss a consent form with you. After you sign the consent form, a phlebotomist will collect a blood sample from you. This will include two (2) 4mL tubes worth of whole blood, which is slightly less than 2 teaspoons. Once the blood has been collected, a trained operator will use your blood sample to perform the RAMP® hs-TnI test. The entire visit should last around 30 minutes.